What is the Future of Immunotherapy?

1

Immunotherapy is a kind of treatment that has had stunning results in some patients with cancers like melanoma, lymphoma, and kidney cancer. Immunotherapy drugs empower the body’s immune system by enabling the body to fight cancer — an approach that can slow or halt cancer in certain patients.

In our latest podcast series, The Science Behind Cancer, we dive into the basics of immunotherapy with the help of Osama Rahma, MD, a medical oncologist at Dana-Farber’s Center for Immuno-Oncology. With Rahma’s help, we explore the different types of immunotherapy, who should be treated with it, how researchers are looking to further develop this treatment, and more.


While some patients with certain cancers have responded well to immunotherapy, Rahma emphasizes that it doesn’t work for everyone. Researchers at Dana-Farber and others around the world are looking at why this is the case — and are also exploring why some cancers eventually become resistant to immunotherapy. Rahma also explains why combination therapy, or the use of more than one type of therapy in treating a patient, is the future of immunotherapy development.

Ultimately, Rahma has a goal: “We are looking to turn cancer into a chronic disease, [in which] immunotherapy can just contain cancer,” he says.

In this episode, we also discuss CAR T-cell therapy, a groundbreaking kind of cellular therapy that uses a patient’s own immune system cells to rally an attack on cancer. CAR T-cell therapy was approved by the FDA for the treatment of adult lymphoma and pediatric acute lymphoblastic leukemia (ALL) in 2017. Approvals for additional usages are expected in 2018.

Learn more about immunotherapy from Dana-Farber.

Comments Sort By Newest

One thought on “What is the Future of Immunotherapy?

  1. How about getting these approvals for additional usages a bit faster, people are dying and these immunotherapy drugs, like Keytruda or CAR-T therapy seems to be working very well for patients. Let’s get moving on these treatments!! 😔😢

  2. How about getting these approvals for additional usages a bit faster, people are dying and these immunotherapy drugs, like Keytruda or CAR-T therapy seems to be working very well for patients. Let’s get moving on these treatments!! 😔😢

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image
Refresh

*

    Make An Appointment

    For adults: 877-960-1562

    Quick access: Appointments as soon as the next day for new adult patients

    For children: 888-733-4662

    All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

    Latest Tweets

    Dana-Farber @danafarber
    It’s not uncommon for #cancer patients to take to a pen after a diagnosis. Peter Rooney’s taken that to another lev… https://t.co/7pN3gmAtjN
    Dana-Farber @danafarber
    People with certain chronic health conditions, including cancer, have a higher risk of becoming ill with the flu. A… https://t.co/tZYmreT9rp
    Dana-Farber @danafarber
    RT @TheJimmyFund: Help us spread kindness today. For every retweet, Cancer Fighters Club will give $10 – up to $4,000 – to support @DanaFar…

    Republish our posts on your blog

    Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.